Sitagliptin is 'Safest' DPP-4 Inhibitor for Type 2 DiabetesSitagliptin is 'Safest' DPP-4 Inhibitor for Type 2 Diabetes
Detailed assessment of heart-failure outcomes from TECOS study with the type 2 diabetes drug sitagliptin is published and confirms that this DPP-4 inhibitor has the safest cardiovascular profile. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Januvia | Study